Aggressive Treatment De-Escalation Feasible in HPV-Positive Oropharyngeal Cancer?

Video
Conference|American Society for Radiation Oncology Annual Meeting (ASTRO)

This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

In this video, Daniel J. Ma, MD, of the Mayo Clinic in Rochester, Minnesota, discusses 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.

Ma presented results of the study (abstract LBA-14) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, held September 24–27 in San Diego.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Related Content
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and Neck

Omar K. Abughanimeh, MBBS;Nicole A. Shonka, MD;Jane Meza, PhD;Lynette Smith, PhD;Irfan A. Vaziri, MD;Mehmet Sitki Copur, MD;Robin High, MBA;Kimberly Shields, BSN, RN;Holly DeSpiegelaere, BSN, RN;Anne Kessinger, MD;Apar Kishor Ganti, MD, MS
August 15th 2025
Article
David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David Sher on the Updated ASTRO Guidelines for Oropharyngeal Cancer

David J. Sher, MD, MPH
August 15th 2025
Podcast
No tracer-related adverse effects were observed in the study, with [18F]AIF-NOTA-PCP2 showing acceptable dosimetry in patients with head and neck cancers.

[18F]AIF-NOTA-PCP2 Shows PD-L1 Monitoring Potential in Head and Neck Cancer

Roman Fabbricatore
August 15th 2025
Article
Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
August 15th 2025
Article
Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer

Adjuvant Nivolumab/Cisplatin/RT Improves DFS in Advanced Head and Neck Cancer

Ariana Pelosci
August 15th 2025
Article
From breast cancer to head and neck tumors, the 2025 ASCO Annual Meeting may feature a wide range of practice-changing data across cancer care.

ASCO 2025: The Presentations That May Shift the Cancer Care Paradigm

Russ Conroy
August 15th 2025
Article